The Heart of the Matter: Novartis

Heart-related illnesses due to high blood pressure present enormous medical, human and economic costs. Strokes, heart attacks and end-stage renal disease are preventable with tight blood pressure control. Controlling high blood pressure with antihypertensive medications benefits the individual and society at large through avoidance of premature death, increased life expectancy, fewer illnesses, better quality of life and lowered costs. That is why Novartis gives special consideration to the social and economic value of its blood pressure medications. This commitment helps to distinguish the company from its competitors, positioning Novartis as a partner of choice to public health institutions when it comes to treatment and prevention of heart-related illness. Image source: wbcsd.org. > Continue.

News selected by Covalence | Country: Global | Company: Novartis | Source: World Business Council for Sustainable Development